Medicines Board Issues New Guidance on Finasteride and Dutasteride amid Suicide Thought Concerns
Teh Medicines Evaluation Board (MEB) has issued a Direct Healthcare Professional Communication (DHPC) regarding Finasteride and dutasteride, outlining new measures designed to mitigate the risk of potential mental health side effects associated with these medications. The announcement follows an earlier MEB message in May 2025,signaling forthcoming risk-limiting updates.
The DHPC details expanded precautions for both drugs. For 1mg Finasteride, product data has been updated to include details regarding the potential for depressive mood, depression, and suicidal ideation, alongside known sexual side effects like reduced libido and erectile dysfunction. Recognizing that these sexual side effects can contribute to mood disturbances, the MEB is also including a patient card with 1mg Finasteride packaging. This card aims to raise awareness among users, encouraging them to seek medical attention promptly if they experience any concerning symptoms.
Dutasteride, which functions similarly to Finasteride, will also receive updated information. while no direct link between Dutasteride and suicidal thoughts has been established, the package leaflet will now include information about the possibility of mood swings as a precautionary measure.
